Causes of Hyperkalemia
Hyperkalemia results from three primary mechanisms: impaired renal potassium excretion (most common), transcellular potassium shifts from intracellular to extracellular space, and excessive potassium intake—with the vast majority of cases involving kidney dysfunction combined with other contributing factors 1, 2.
Primary Mechanisms
1. Impaired Renal Excretion (Most Common)
The kidneys normally excrete approximately 90% of daily potassium intake 1. Hyperkalemia develops when renal excretion is limited by:
- Reduced glomerular filtration rate (GFR): Risk progressively increases as eGFR decreases, particularly below 60 mL/min/1.73 m², with substantially elevated risk when eGFR falls below 15 mL/min/1.73 m² 1, 3
- Decreased tubular flow and distal sodium delivery 3
- Reduced aldosterone activity or expression of aldosterone-sensitive ion transporters in the distal nephron 3
2. Transcellular Potassium Shifts
Potassium moves from the intracellular space (98% of total body potassium) to the extracellular space (only 2% of total body potassium) 1. This redistribution can rapidly elevate serum levels even without changes in total body potassium.
3. Excessive Potassium Intake
While increased dietary intake alone rarely causes hyperkalemia in patients with normal kidney function, it becomes problematic when combined with impaired renal excretion 1, 2.
High-Risk Patient Populations
Certain conditions dramatically increase hyperkalemia risk 1:
- Chronic kidney disease (CKD), especially stages 4-5
- Heart failure (HF)
- Diabetes mellitus
- Resistant hypertension
- Myocardial infarction
- Advanced age
Patients with CKD who experience hyperkalemia have 3.8-fold higher acute hospitalization rates and 4.9-fold higher mortality compared to matched patients without hyperkalemia 4.
Medication-Induced Hyperkalemia
RAASi medications are the most clinically significant pharmacologic cause 4, 1:
- Angiotensin-converting enzyme inhibitors (ACEi)
- Angiotensin receptor blockers (ARBs)
- Angiotensin receptor-neprilysin inhibitors
- Mineralocorticoid receptor antagonists (MRAs), both steroidal and non-steroidal
Additional medications that elevate potassium 1:
- Potassium-sparing diuretics
- Heparin
- β-blockers
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Calcineurin inhibitors
- Trimethoprim
- Pentamidine
The combination of RAASi therapy with eGFR <60 mL/min/1.73 m² creates particularly high risk, which escalates as kidney function declines 1.
Hypoaldosteronism
This often-overlooked cause can produce hyperkalemia even with normal or mildly impaired kidney function 2. Aldosterone deficiency impairs potassium excretion in the distal nephron independent of GFR.
Pseudohyperkalemia
This represents falsely elevated potassium measurements without true elevation in vivo 2. Common causes include:
- Hemolysis during blood draw
- Prolonged tourniquet application
- Fist clenching during phlebotomy
- Thrombocytosis or leukocytosis (potassium release from cells after collection)
This diagnosis is frequently missed in clinical practice but is critical to identify to avoid unnecessary treatment 2.
Risk Factors for Recurrent Hyperkalemia
After an initial hyperkalemia episode, specific factors predict recurrence within 6 months 1:
- Moderate to severe initial hyperkalemia (≥5.6 mEq/L)
- Low eGFR (<45 mL/min/1.73 m²)
- Diabetes mellitus
- Spironolactone use
Clinical Context
The risk of hyperkalemia increases significantly with every 0.1 mEq/L rise in serum potassium ≥5.0 mEq/L, directly correlating with all-cause mortality 4. Severe hyperkalemia (≥6.5 mEq/L) requiring hospitalization carries inpatient mortality rates up to 31% 4.
Common Pitfalls
- Failing to recognize that most hyperkalemia results from multiple concurrent factors, not a single cause 1, 2
- Missing pseudohyperkalemia, leading to inappropriate treatment and potential harm 2
- Overlooking hypoaldosteronism in patients with preserved kidney function 2
- Not recognizing that acute illnesses like fever or diarrhea can precipitate severe hyperkalemia in high-risk patients 5